1. Home
  2. GCTK vs ARTL Comparison

GCTK vs ARTL Comparison

Compare GCTK & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCTK

GlucoTrack Inc.

N/A

Current Price

$0.37

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$0.80

Market Cap

2.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GCTK
ARTL
Founded
2001
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.6M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
GCTK
ARTL
Price
$0.37
$0.80
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
17.6M
120.0K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.65
N/A
Revenue
$589,462.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.71
52 Week High
$14.14
$19.91

Technical Indicators

Market Signals
Indicator
GCTK
ARTL
Relative Strength Index (RSI) 46.86 37.29
Support Level $0.28 $0.71
Resistance Level $0.68 $1.87
Average True Range (ATR) 0.13 0.08
MACD -0.01 0.02
Stochastic Oscillator 19.37 26.83

Price Performance

Historical Comparison
GCTK
ARTL

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: